Zurcher Kantonalbank Zurich Cantonalbank Has $237,000 Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 11.8% during the fourth quarter, HoldingsChannel reports. The firm owned 10,338 shares of the company’s stock after acquiring an additional 1,093 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Protagonist Therapeutics were worth $237,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of Protagonist Therapeutics by 2.6% during the third quarter. Vanguard Group Inc. now owns 3,228,394 shares of the company’s stock worth $53,850,000 after purchasing an additional 80,639 shares during the period. Kynam Capital Management LP raised its position in Protagonist Therapeutics by 86.5% in the 3rd quarter. Kynam Capital Management LP now owns 1,818,657 shares of the company’s stock valued at $30,335,000 after buying an additional 843,359 shares during the last quarter. Braidwell LP acquired a new stake in Protagonist Therapeutics in the 3rd quarter valued at approximately $18,501,000. FMR LLC raised its position in Protagonist Therapeutics by 0.4% in the 3rd quarter. FMR LLC now owns 509,242 shares of the company’s stock valued at $8,494,000 after buying an additional 1,835 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Protagonist Therapeutics by 4.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 439,102 shares of the company’s stock valued at $7,324,000 after buying an additional 19,492 shares during the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Insiders Place Their Bets

In other Protagonist Therapeutics news, CFO Asif Ali sold 1,234 shares of the business’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $25.11, for a total transaction of $30,985.74. Following the completion of the transaction, the chief financial officer now owns 37,163 shares of the company’s stock, valued at $933,162.93. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Dinesh V. Ph D. Patel sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $28.31, for a total value of $707,750.00. Following the completion of the transaction, the chief executive officer now owns 549,590 shares of the company’s stock, valued at $15,558,892.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Asif Ali sold 1,234 shares of the company’s stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $25.11, for a total value of $30,985.74. Following the completion of the transaction, the chief financial officer now directly owns 37,163 shares of the company’s stock, valued at approximately $933,162.93. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 83,457 shares of company stock valued at $2,553,328. 5.00% of the stock is currently owned by corporate insiders.

Protagonist Therapeutics Stock Down 0.1 %

NASDAQ:PTGX opened at $26.06 on Tuesday. The firm has a market capitalization of $1.53 billion, a price-to-earnings ratio of -17.49 and a beta of 2.09. Protagonist Therapeutics, Inc. has a twelve month low of $13.72 and a twelve month high of $33.34. The stock’s 50 day moving average price is $28.03 and its two-hundred day moving average price is $23.79.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Tuesday, February 27th. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.05 by $0.39. The business had revenue of $60.00 million for the quarter, compared to analyst estimates of $60.00 million. As a group, analysts anticipate that Protagonist Therapeutics, Inc. will post 1.18 earnings per share for the current year.

Analyst Ratings Changes

PTGX has been the topic of a number of recent research reports. StockNews.com raised Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, February 28th. JPMorgan Chase & Co. lifted their target price on Protagonist Therapeutics from $34.00 to $37.00 and gave the company an “overweight” rating in a research report on Wednesday, February 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $38.00 price target on shares of Protagonist Therapeutics in a research report on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $36.00.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.